

Multidrug therapy against leprosy

**Development and implementation
over the past 25 years**



**World Health Organization
Geneva
2004**

WHO Library Cataloguing-in-Publication Data

Multidrug therapy against leprosy : development and implementation over the past 25 years
/ [editor]: H. Sansarricq.

1.Leprosy - drug therapy 2.Leprostatic agents - therapeutic use 3.Drug therapy, Combination 4.Health plan implementation - trends 5.Program development 6.World Health Organization I.Sansarricq, Hubert.

ISBN 92 4 159176 5 (NLM classification: WC 335) WHO/CDS/CPE/CEE/2004.46

© World Health Organization 2004

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

Acknowledgements	v
Foreword	vii
<i>Carlos Morel</i>	
Introduction	1
The saga of dapsone <i>M.F. Lechat</i>	
Improved knowledge and new hopes <i>H. Sansarricq, S.R. Pattyn</i>	
The UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases <i>V. Pannikar</i>	
Chapter 1. Preparation of the Study Group on Chemotherapy of Leprosy	19
1.1 Scientific factors (1972–1981)	19
<i>L. Levy</i>	
1.2 Increasing role of voluntary organizations	25
The Japan Shipbuilding Industry Foundation and the Sasakawa Memorial Health Foundation <i>Y. Yuasa</i>	
The International Federation of Anti-Leprosy Associations <i>H. Sansarricq</i>	
Chapter 2. The Study Group	31
<i>H. Sansarricq</i>	
2.1 The problem	31
Effective and practical MDT in sight? The anarchic use of rifampicin A strong demand for WHO recommendations The response from WHO	
2.2 The meeting	35
Design of the meeting Progress in discussions The final report	

Chapter 3. Implementation of MDT	45
3.1 Successive steps	45
<i>D. Daumerie</i>	
Main events, 1982 onwards	
1982–1985: Introduction of MDT	
1986–1990: Expansion of MDT into the “less difficult” areas	
1991–2000: Elimination of leprosy as a public health problem	
2000 onwards: the Final Push	
3.2 Some important factors contributing to the implementation of WHO MDT	58
<i>M.F. Lechat</i>	
Wide acceptance of MDT	
Extremely low relapse rates after MDT treatment	
3.3 Technical difficulties in the expansion of MDT	64
<i>S.K. Noordeen</i>	
Chapter 4. The role of countries	69
4.1 Implementation of WHO MDT in Brazil	69
<i>A. Andrade</i>	
Serious reservations about the introduction of WHO MDT	
Treatment regimens tested	
Factors that convinced the experts to adopt the WHO MDT regimen	
Adjustment of the norms and guidelines of the leprosy control programme to implement WHO MDT	
Changes in the epidemiological situation, impact, side-effects, relapses, and cure	
The impact of MDT	
Lessons learned	
4.2 Implementation of MDT in Burkina Faso	82
<i>A. Tiendrebeogo, L. Some</i>	
Introduction of MDT: 1981–1988	
Extension of MDT coverage: 1989–1993	
Leprosy elimination: 1994–2000	
4.3 Implementation of WHO MDT in India 1982–2001	92
<i>C.K. Rao</i>	
Progress	
Developments	
Conclusion	

4.4	Implementation of WHO MDT in Myanmar	106
	<i>Kyaw Lwin, Tin Myint, Mg Mg Gyi, Mya Thein, Tin Shwe, Kyaw Nyunt Sein</i>	
	History of leprosy	
	Leprosy control in Myanmar	
	Situation during the early 1980s	
	Challenges faced	
	Finding alternative regimens (1981–1986)	
	Introduction of WHO MDT, 1988	
	Expansion of MDT coverage, 1995–1996	
	Achievements due to integrated MDT services	
	Conclusion	
4.5	Implementation of WHO MDT in the Philippines, 1981–2000	117
	<i>S.S. Griño</i>	
	The pilot study	
	National leprosy control programme	
	Strengths – factors that contributed to success	
	Conclusion	
Chapter 5.	The role of international agencies and nongovernmental organizations	127
5.1	The Nippon Foundation (formerly Japan Shipbuilding Industry Foundation) and the Sasakawa Memorial Health Foundation	127
	<i>Y. Yuasa</i>	
5.2	The International Federation of Anti-Leprosy Associations	129
	<i>H. Sansarricq</i>	
	1981–1990: continuing good ILEP/WHO cooperation, with a few clouds	
	1991–2000: growing difficulties in ILEP/WHO cooperation	
5.3	Novartis	135
	<i>S.J. Yawalkar, P. Grewal</i>	
	Drug development	
	Contribution to implementation of WHO MDT	
Chapter 6.	The role of WHO including TDR	143
6.1	The WHO Leprosy unit	143
	Overview	
	<i>S.K. Noordeen</i>	
	Detailed account	
	<i>H. Sansarricq</i>	

6.2	THELEP	160
	<i>L. Levy</i>	
	Surveys of dapsone resistance	
	Information regarding antileprosy drugs	
	Participation in the 1981 Study Group and in subsequent technical meetings related to chemotherapy of leprosy	
6.3	Evolution in WHO, including TDR/THELEP, from 1991 to 2000	165
	Intensive elimination strategy	
	<i>S.K. Noordeen</i>	
	Changes in research focus	
	<i>L. Levy</i>	
Chapter 7.	Lessons to be learned	171
	<i>H. Sansarricq</i>	
7.1	MDT development	171
	Overview	
	MDT drugs	
	THELEP	
	Moving closer to the Study Group regimens	
	Conclusion	
7.2	1982–1990: the first years of MDT implementation	173
	MDT coverage	
	Technical aspects	
	The reasons for success	
	Conclusion	
7.3	1991–2000: elimination strategy	175
	Resolution WHA44.9 and plan for elimination of leprosy as a public health problem	
	Implementation of the elimination strategy	
7.4	2000 onwards: the final push	178
7.5	Current concerns	178

Acknowledgements

The Editor wishes to thank the persons listed below for their special written contributions and for providing background data.

Dr H. Sansarricq, Editor

Contributors

Dr V.L. Gomes de Andrade (Brazil); Mrs S.S. Griño (Philippines); Drs Kyaw Lwin, Tin Myint, Mg Mg Gyi, Mya Thein, Tin Shwe, Kyaw Nyunt Sein (Myanmar); Professor M.F. Lechat (Belgium); Dr L. Levy (Israel); Dr S.K. Noordeen (India); Dr S.R. Pattyn (Belgium); Dr C.K. Rao (India); Dr L. Some and Dr A. Tiendrebeogo (Burkina Faso); Professor S.J. Yawalkar and Mrs P. Grewal (Switzerland); Dr Y. Yuasa (Japan).

WHO Secretariat

Dr D. Daumerie; Dr V. Pannikar.

The Leprosy Programme would like to pay special tribute to Dr Hubert Sansarricq. Using his broad knowledge of the Programme's work, he participated extensively in the preparation of the report, generously dedicating much of his time to this substantial undertaking.

Special thanks are also addressed to our English Editor, Mrs Sarah Balance.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30094

